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1. INTRODUCTION {#ajh25727-sec-0001}
===============

Sickle cell disease (SCD) is caused by a genetic mutation whereby sickle hemoglobin (*HbS*) polymerizes in its deoxygenated form, leading to impaired oxygen transport and chronic hemolytic anemia. In SCD, acute anemia increases the risk for silent cerebral infarcts (SCI),[1](#ajh25727-bib-0001){ref-type="ref"}, [2](#ajh25727-bib-0002){ref-type="ref"}, [3](#ajh25727-bib-0003){ref-type="ref"} despite elevated cerebral blood flow (CBF) to compensate anemia.[4](#ajh25727-bib-0004){ref-type="ref"}, [5](#ajh25727-bib-0005){ref-type="ref"}, [6](#ajh25727-bib-0006){ref-type="ref"} Interruptions to CBF are associated with ischemic risk,[7](#ajh25727-bib-0007){ref-type="ref"} and MRI studies have shown a high prevalence of SCI in both children and adults with SCD.[8](#ajh25727-bib-0008){ref-type="ref"} While overt stroke is preventable with transfusion therapy,[9](#ajh25727-bib-0009){ref-type="ref"} SCI still remain poorly understood, and advances in MR technology are becoming more instrumental in our investigation of SCI development and progression in SCD.[10](#ajh25727-bib-0010){ref-type="ref"} For instance, SCIs are associated with cognitive impairment and lesion progression in adults with SCD,[11](#ajh25727-bib-0011){ref-type="ref"}, [12](#ajh25727-bib-0012){ref-type="ref"}, [13](#ajh25727-bib-0013){ref-type="ref"} and indicate that the balance between oxygen demand and delivery, which serves to maintain cerebral metabolism, may be disrupted.

The cerebral metabolic rate of oxygen (CMRO~2~) quantitatively describes the rate of oxygen consumption by metabolic processes in cerebral tissue. The CMRO~2~ is high in healthy children to meet the metabolic demands of the developing brain, particularly between the ages of 2 and 10 years,[14](#ajh25727-bib-0014){ref-type="ref"} which is also the age range in which overt stroke has the highest incidence in SCD.[9](#ajh25727-bib-0009){ref-type="ref"}, [15](#ajh25727-bib-0015){ref-type="ref"} Hence, CBF can be particularly high in children with SCD in whom anemia and metabolic requirements play an additive role in increasing blood flow and associated increased risk of overt stroke.[16](#ajh25727-bib-0016){ref-type="ref"}, [17](#ajh25727-bib-0017){ref-type="ref"} Note that CMRO~2~ typically declines with age[18](#ajh25727-bib-0018){ref-type="ref"}, [19](#ajh25727-bib-0019){ref-type="ref"} and CBF matches oxygen delivery to this change in metabolic demand.[20](#ajh25727-bib-0020){ref-type="ref"} Oxygen extraction fraction (OEF) measured by MRI can serve as a non‐invasive measure of the efficacy of oxygen supply‐demand mechanisms.[20](#ajh25727-bib-0020){ref-type="ref"} Studies in adult patients with SCD have varied in their methods and conclusions as to whether CMRO~2~ is maintained in the presence of chronic demands on CBF to counteract anemia.[21](#ajh25727-bib-0021){ref-type="ref"}, [22](#ajh25727-bib-0022){ref-type="ref"}, [23](#ajh25727-bib-0023){ref-type="ref"}

In SCD, cerebrovascular reserve is reduced,[24](#ajh25727-bib-0024){ref-type="ref"}, [25](#ajh25727-bib-0025){ref-type="ref"}, [26](#ajh25727-bib-0026){ref-type="ref"} in particular, CBF may already be maximally recruited for basal oxygen demands and might even be unable to maintain the required CMRO~2~ in periods of increased metabolic needs. This infers a risk of insufficient oxygen in acute anemic periods,[1](#ajh25727-bib-0001){ref-type="ref"} particularly to regions where CBF is already relatively low.[27](#ajh25727-bib-0027){ref-type="ref"}, [28](#ajh25727-bib-0028){ref-type="ref"}, [29](#ajh25727-bib-0029){ref-type="ref"} Recent work shows that oxygen metabolism could actually decrease if CBF increases in the presence of capillary transit time heterogeneity (CTH).[30](#ajh25727-bib-0030){ref-type="ref"} A potential effect offsetting this microvascular shunting is that anemia induces a rightward shift in oxygen‐dissociation, allowing more efficient oxygen diffusion in SCD. While these opposing processes are challenging to disentangle, and may cancel out, we tested the hypothesis that CMRO~2~ is reduced in adult patients with SCD as a result of chronic anemia and impaired vascular reserve capacity, which may also explain the high prevalence of (silent) cerebral infarcts in this population.[31](#ajh25727-bib-0031){ref-type="ref"} The second hypothesis was that vasodilation can improve CMRO~2~ by generating an increase in blood and oxygen flow. Accordingly, the aim of this study was to examine CMRO~2~ using specialized MRI techniques[32](#ajh25727-bib-0032){ref-type="ref"}, [33](#ajh25727-bib-0033){ref-type="ref"}, [34](#ajh25727-bib-0034){ref-type="ref"} in adults with SCD without a clinical history of stroke, and to measure the response to vasodilation with acetazolamide[35](#ajh25727-bib-0035){ref-type="ref"}, [36](#ajh25727-bib-0036){ref-type="ref"} to better understand the etiology of ischemic risk in these patients.

2. METHODS {#ajh25727-sec-0002}
==========

2.1. Participants {#ajh25727-sec-0003}
-----------------

This cross‐sectional study was approved by the local Institutional Review Board (IRB) at the Amsterdam University Medical Centers (Amsterdam UMC, Location AMC) in The Netherlands, and carried out in accordance with the Declaration of Helsinki. This study was registered at <http://clinicaltrials.gov> under the ID: NCT02824406. All participants provided informed consent prior to study participation. Inclusion criteria were adults (\>18 years) with SCD (*HbSS* or *HbS*β^0^‐thalassaemia) recruited from the outpatient clinic at the Amsterdam UMC. Age‐, sex‐, and race‐matched healthy controls were recruited from friends and relatives of the participating patients. Exclusion criteria were contraindications to MRI and acetazolamide, and a clinical history of stroke, a cerebrovascular accident or neurologic disease affecting cerebral autoregulation. Additionally, patients were in steady state at the time of the MRI examination. Steady state was defined as no infection or hospitalization for a painful crisis in the month prior to participation. The cohort has previously been described in Václavů et al.[26](#ajh25727-bib-0026){ref-type="ref"} One patient was receiving blood transfusions for prevention of stroke upon detection of high TCD values while still in pediatric care, and two other patients were on transfusions for prevention of frequent hydroxyurea refractory vaso‐occlusive crises/acute chest syndrome.

2.2. Blood markers {#ajh25727-sec-0004}
------------------

Blood samples were drawn from an antecubital vein in all participants, and an intravenous catheter was placed at the site of cannulation directly prior to MRI for acetazolamide administration during the scan. Genotype (*HbAA*, *HbAS*, *HbSS* or *HbS*β^0^) was confirmed with high performance liquid chromatography (HPLC) and DNA analysis. The following parameters were analyzed for their association with CMRO~2~: hemoglobin, (HB) hematocrit (Hct), MCV, leukocyte and platelet counts, *HbS%* and fetal hemoglobin (*HbF* %), creatinine, ASAT, ALAT, and plasma ferritin levels. Surrogate markers for hemolysis were defined as LDH, reticulocytes, and bilirubin levels.

2.3. MR imaging {#ajh25727-sec-0005}
---------------

All images were acquired on a 3 T Ingenia clinical MR system (Philips Healthcare, Best, The Netherlands) using a 32‐channel receive head‐coil and body‐coil transmission. The MRI protocol is depicted in Figure [1A](#ajh25727-fig-0001){ref-type="fig"}, and comprised MR angiography (MRA) for vasculopathy, fluid‐attenuated inversion recovery (FLAIR) for anatomy and lesions, T~2~‐prepared tissue relaxation with inversion recovery (T~2~‐TRIR) for venous blood oxygen saturation and T~1~ of blood, and pseudo continuous arterial spin labelling (pCASL) for cerebral blood flow.

![MRI procedures. A, The sequence started with an MRA and FLAIR scan for vasculopathy, anatomy and lesions, followed by a baseline T~2~ measurement (T~2~‐TRIR), and baseline pseudo‐continuous arterial spin labelling (pCASL) scan during which acetazolamide was administered intravenously. The T~2~ measurement was repeated 25 minutes after the injection. B, A mask for cerebral blood flow (CBF) was obtained from the segmented gray matter (GM) and white matter (WM) tissue volumes with lesions removed. C, Measurement of the T~2~‐TRIR plane is shown in as a red line representing perpendicular placement to the sagittal sinus. The sagittal sinus was detected automatically (shown in red) and the fit was initiated in the voxels contained in this mask. D, The data points and fit of the average of the voxels from one participant is shown for T~1~ of all the effective echo times (eTE, 0, 40, 80, and 160 ms). Essentially, the T~2~ decay curve can be obtained from any four points (four eTEs) belonging to each time point along the x‐axis, but to increase the robustness the T~2~ curve was fitted simultaneously with the T~1~ curve in all acquired time points using a least squares minimizing function \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](AJH-95-401-g001){#ajh25727-fig-0001}

Lesions and brain volume were assessed using a high resolution T~2~‐weighted 3D multi‐shot TSE fluid attenuated inversion recovery (FLAIR) sequence with a FOV 250 x 250 x 180 mm, voxel size 0.98 x 0.98 x 1.12 mm, TR/TE 4800/356 ms, SENSE acceleration factor AP/FH 2.6/2, SPAIR fat suppression, inversion delay 1650 ms, flip angle 90°and scan duration of 5:11 minutes.

Vasculopathy was assessed in maximum intensity projection reconstructions of right‐left and feet‐head projections and in magnitude images of non‐contrast enhanced 3D T1 time‐of‐flight FFE RF‐spoiled gradient echo inflow angiography MRA (TR/TE 21/4 ms, FOV 200 x 200 x 90 mm, voxel size 0.39 x 0.39 x 0.5 mm, flip angle 20°, 180 axial slices, scan duration 5:45 minutes).

Venous blood T~1~ and T~2~ were simultaneously measured in the sagittal sinus with a T~2~‐TRIR sequence consisting of a global slab‐selective frequency offset corrected inversion (FOCI) pulse and T~2~ preparation preceding a single slice 2D single‐shot FFE EPI Look‐Locker read‐out.[33](#ajh25727-bib-0033){ref-type="ref"}, [34](#ajh25727-bib-0034){ref-type="ref"}, [37](#ajh25727-bib-0037){ref-type="ref"} The parameters of the T~2~‐TRIR were FOV 202 x 243 mm, voxel size 1.69 x 1.69 x 4 mm, 1 transverse slice placed perpendicular to the posterior sagittal sinus, TR/TE 150/24 ms, SENSE acceleration factor AP 3, and four T~2~ weightings resulting in effective echo times (eTE) of 0, 40, 80, and 160 ms. This corresponded to 0, 4, 8 and 16 refocusing pulses in the MLEV T~2~‐preparation with a Carr‐Purcell‐ Meiboom‐Gill interpulse spacing of τCPMG =10 ms, TI1 10 ms, ∆TI 130 ms, 4 dynamic scans, a Look‐Locker read‐out with high flip angles (95°) to ensure brain tissue saturation, and a total scan duration of 50 seconds.

Cerebral blood flow was measured in the whole brain using a 2D gradient‐echo single‐shot EPI pCASL sequence with the following parameters: FOV 240 x 240 x 133 mm, voxel size 3 x 3 x 7 mm, 19 slices, labelling duration 1800 ms, post‐labeling delay 1800 ms, flip angle 90°, TR/TE 4400/14 ms, and a SENSE acceleration factor AP 2.5. Additional parameters were SPIR fat suppression, two background tissue suppression pulses, 140 control‐label pairs, and total scan duration of 20 minutes. The labelling plane was manually placed 90 mm below the middle slice of the imaging volume, and perpendicular to the brain feeding arteries visualized on a phase contrast MRA scout scan. Balanced pCASL labelling with flip angles of 27.81°, radio frequency interval and duration of 1.21 ms and 0.48 ms, and gradient strength average and maximum of 0.36 mT/m and 5.0 mT/m were used. A magnetization equilibrium (M0) scan was acquired for CBF quantification using the same parameters as pCASL, except that labelling and background suppression were switched off.

2.4. Vasodilatory challenge {#ajh25727-sec-0006}
---------------------------

Following the baseline scans, an intravenous bolus of 16 mg/kg acetazolamide (dissolved in 20 mL saline, 0.9% NaCl) was infused at a flow rate of 0.1 mL/sec and flushed with 10 mL saline. The T~2~‐TRIR scans were repeated 25 minutes after the start of the acetazolamide injection when vasodilation has typically reached a maximum.[35](#ajh25727-bib-0035){ref-type="ref"}, [38](#ajh25727-bib-0038){ref-type="ref"}

2.5. Image analysis {#ajh25727-sec-0007}
-------------------

Vessel stenosis was assessed in the circle of Willis vessels on MRA and vasculopathy was defined as \>50% narrowing of a vessel or presence of comorbid Moyamoya. Presence of white matter hyperintensities was defined as ≥2 lesions ≥5 mm in diameter, where diameter was defined as the maximum length along a major axis of a lesion in 3D as described previously.[26](#ajh25727-bib-0026){ref-type="ref"}

2.6. SvO~2~, OEF, CaO~2~, DO~2~ and CMRO~2~ quantification {#ajh25727-sec-0008}
----------------------------------------------------------

An example of the masked region of interest is shown in Figure [1C](#ajh25727-fig-0001){ref-type="fig"}. The T~1~ and T~2~ were simultaneously fitted by a least‐squares minimizing algorithm designed to find the combination of voxels in the sagittal sinus ROI resulting in the lowest residual error of fitted T~1~ and T~2~ values from the following model:$$M\left( {TI} \right) = M0\left\lbrack {1 - \left( {1 + e^{- \frac{\mathit{eTE}}{T_{2}}} \bullet {IE}\ } \right) \bullet e^{- \frac{\mathit{TI}}{T_{1}}}} \right\rbrack$$where is the longitudinal magnetization of blood at each inversion recovery time , is the equilibrium magnetization of blood, is the effective echo time and is inversion efficiency. An example of the exponential T~1~ and T~2~ decay of blood within the sagittal sinus is shown in Figure [1D](#ajh25727-fig-0001){ref-type="fig"}. The resulting T~2~ values were converted to venous oxygen saturation (SvO~2~) using a recently developed model,[22](#ajh25727-bib-0022){ref-type="ref"}, [39](#ajh25727-bib-0039){ref-type="ref"} for sickle cell disease patients:$$R_{2}\left( s^{- 1} \right) = 70*\left( {1 - {SvO}_{2}} \right) + 5.75$$and for healthy controls:$$R_{2}\left( s^{- 1} \right) = 77.5*{Hct}*\left( {1–{SvO}_{2}} \right)^{2} + 27.8*\left( {1–{SvO}_{2}} \right)^{2} + 6.95*{Hct} + 2.34$$where R~2~ = 1/T~2~, Hct is the measured Hct. The equation was solved for venous oxygen saturation (SvO~2~) in each subject before and after acetazolamide. Since arterial oxygenation (SaO~2~) in the brain is similar to that in the periphery, and can be assumed to be normal in the absence of cardio‐pulmonary disease, we assumed SaO~2~ was equal to 0.98, or almost fully saturated. Subsequently, the oxygen extraction fraction (OEF) was calculated using the formula:$${OEF}\left( \% \right) = \left( {{SaO}_{2} - {SvO}_{2}} \right)/{SaO}_{2}*100$$

Oxygen carrying capacity (CaO~2~) was calculated from measured hemoglobin (HB, g/dL) using the formula:$$\mathsf{CaO}_{2}\ \left( {\text{μmol}\ O_{2}/100\mspace{2mu}{mL}\mspace{9mu}\text{blood}} \right) = \left\lbrack {\left( {{HB}\mspace{9mu} x\mspace{9mu} 1.34\mspace{9mu} x\mspace{9mu}{SaO}_{2}} \right) + \left( {0.003\ x\ {pO}_{2}} \right)} \right\rbrack/22.4*1000$$Where HB is hemoglobin concentration in g/100 mL obtained from blood samples, 1.34 mL/g is the constant representing the amount of oxygen that can bind to HB, 0.0031 (mL O~2~/mmHg O~2~/100 mL blood) is the solubility coefficient of oxygen in human plasma, and pO~2~ in mmHg is the arterial oxygen tension of 1. Unit conversion of oxygen carrying capacity (CaO~2~) to molar concentrations was performed by dividing by 22.4\*1000 obtained from the gas law equation at standard temperature and pressure (PV = nRT, where *P* is pressure of 1 atm, *V* is volume in L, *n* is 1 mol, *R* is the ideal gas law constant of 0.08206 L atm/\[mol K\] and *T* is 273 Kelvin). One μmol at standard chemical conditions occupies 0.0224 mL, so to substitute mL O~2~ for μmol O~2~ in the CaO~2~ equation, we divided it by 44.64 mL/μmol. Then, CMRO~2~ was calculated according to Fick\'s principle:$$\text{CMRO}_{2}\ \left( {\text{μmol}\ O_{2}/10\text{0g}/\min} \right) = {CBF}\ x\ {OEF}\ x\ {CaO}_{2}$$

Finally, oxygen delivery (DO~2~) was calculated by:$${DO}_{2}\ \left( {\text{μmol}\ O_{2}/10\text{0g}/\min} \right) = {CBF}\ x\ {CaO}_{2}$$

The CMRO~2~ was calculated in the whole brain (calculated from CBF in GM plus WM minus lesions Figure [1B](#ajh25727-fig-0001){ref-type="fig"}) with CBF quantified with a two‐compartment model as described previously.[26](#ajh25727-bib-0026){ref-type="ref"}

2.7. Statistical analysis {#ajh25727-sec-0009}
-------------------------

Statistical analyses were performed in R 3.4.3 (R Core Team \[2017\] R Foundation for Statistical Computing, Vienna, Austria). First, Shapiro‐Wilk normality test was used, and subsequently Wilcoxon rank sum (significant non‐normal distribution) or *t* test (normal distribution) for group differences. Paired tests were used to assess statistical significance of changes from baseline to post‐acetazolamide conditions. *P* \< .05 was considered significant. Variables were summarized by means and standard deviations. Associations between CMRO~2~ and blood values were assessed using linear regression to determine if the slope was significantly different from zero. A Benjamini‐Hochberg adjustment for family‐wise error was performed to correct for multiple comparisons.

3. RESULTS {#ajh25727-sec-0010}
==========

3.1. Participant characteristics {#ajh25727-sec-0011}
--------------------------------

The baseline characteristics of the 38 patients and 11 healthy controls that were included are presented in Table [1](#ajh25727-tbl-0001){ref-type="table"}. 14 patients were using hydroxyurea medication and three were receiving transfusions, of which two were also on hydroxyurea medication.

###### 

Baseline characteristics and MRI parameters in healthy controls and patients with sickle cell disease

+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
|                                     | Controls          |               |             | Patients with SCD  |              |             | *P‐*value  |
+:====================================+:==================+:==============+:============+:===================+:=============+:============+:===========+
| **Baseline characteristic**         | **(n = 11)**      |               |             | **(n = 38)**       |              |             | **Groups** |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| Age \[yrs\]                         | 37.36 ± 15.43     |               |             | 32.08 ± 11.14      |              |             | .31        |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| Sex                                 | 55% male          |               |             | 63% male           |              |             | ‐          |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| Genotype                            | HbAA (n = 9, 82%) |               |             | HbSS (n = 33, 87%) |              |             | ‐          |
|                                     |                   |               |             |                    |              |             |            |
|                                     | HbAS (n = 2, 18%) |               |             | HbSβ0 (n = 5, 13%) |              |             | ‐          |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| Hydroxyurea, n \[%\]                | ‐                 |               |             | 13 (37)            |              |             | ‐          |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| Average dose mg/kg                  | ‐                 |               |             | 15.88 ± 2.94       |              |             | ‐          |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| Chronic blood transfusions, n \[%\] | ‐                 |               |             | 3 (9)              |              |             | ‐          |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| Vasculopathy (%)                    | ‐                 |               |             | 1 (2)              |              |             | ‐          |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| SCI status                          | 4 (45)            |               |             | 31 (82)            |              |             | **‐**      |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| Volume of lesions \[mL\]            | 0.04 \[IQR 0.54\] |               |             | 0.59 \[IQR 2.99\]  |              |             |            |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| Hematocrit \[%\]                    | 42 ± 3            |               |             | 26 ± 4             |              |             | **\<.001** |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| Hemoglobin \[g/dL\]                 | 13.7 ± 1.3        |               |             | 8.8 ± 1.4          |              |             | **\<.001** |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| HbS%                                | 36.9 ± 0.4        |               |             | 80.4 ± 15.1        |              |             | **\<.001** |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| HbF%                                | ‐                 |               |             | 9.4 ± 7.6          |              |             | **‐**      |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| CaO~2~ \[μmol O~2~/100mL blood\]    | 804 ± 73          |               |             | 515 ± 81           |              |             | **\<.001** |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| **MRI parameter**                   | **Baseline**      | **Post‐ACZ**  | **Δ**       | **Baseline**       | **Post‐ACZ** | **Δ**       | **Groups** |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| T~1b~ \[s\]                         | 1.76 ± 0.09       | 1.69 ± 0.11   | 0.11        | 1.81 ± 0.10        | 1.71 ± 0.09  | **\<0.001** | .23        |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| T~2b~ \[ms\]                        | 77.6 ± 10.9       | 124.5 ± 22.7  | **\<0.001** | 88.0 ± 13.3        | 115.4 ± 20.2 | **\<0.001** | **.04**    |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| CBF \[mL/100/min\]                  | 45.7 ± 4.8        | 76.2 ± 9.5    | **\<0.001** | 73.9 ± 16.0        | 97.0 ± 17.9  | **\<0.001** | **\<.001** |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| SvO~2~ \[%\]                        | 64.1 ± 3.8        | 78.7 ± 7.0    | **\<0.001** | 71.4 ± 4.3         | 79.4 ± 5.7   | **\<0.001** | **\<.001** |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| DO~2~ \[μmol O~2~ /100g/min\]       | 368.1 ± 42.3      | 616.0 ± 105.3 | **\<0.001** | 377.1 ± 66.8       | 499.4 ± 87.4 | **\<0.001** | .69        |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| OEF \[%\]                           | 35.3 ± 3.6        | 19.7 ± 7.1    | **\<0.01**  | 27.1 ± 4.4         | 19.0 ± 5.8   | **\<0.001** | **\<.001** |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+
| CMRO~2~ \[μmol O~2~/100g/min\]      | 127.2 ± 19.5      | 122.8 ± 43.8  | 0.78        | 101.7 ± 23.6       | 91.0 ± 29.5  | **\<0.01**  | **\<.01**  |
+-------------------------------------+-------------------+---------------+-------------+--------------------+--------------+-------------+------------+

Bold values indicate statistical significance.

Abbreviations: ACZ, acetazolamide; SCD, sickle cell disease; CaO~2~, Oxygen carrying capacity of blood was calculated from hemoglobin so does not represent a separate measure; HbS% and HbF% is reported for the n = 2 controls that had the HbAS genotype; CBF, whole brain cerebral blood flow; CMRO~2~, cerebral metabolic rate of oxygen; DO~2~, oxygen delivery; IQR, interquartile range; OEF, oxygen extraction fraction; SvO~2~, venous oxygen saturation; T~1b~, longitudinal relaxation time of blood; T~2b~, transverse relaxation time of blood; Δ, within‐group change after acetazolamide.

3.2. Elevated venous oxygen saturation (SvO~2~) in SCD {#ajh25727-sec-0012}
------------------------------------------------------

In the patient group, T~2~ fitting failed in two cases. Therefore 36 patients were included in the T~2~, OEF, and CMRO~2~ analysis. In the healthy control group, initially consisting of 11 healthy volunteers, two fits failed. The remaining fits were robust, as shown in the example in Figure [1D](#ajh25727-fig-0001){ref-type="fig"}. The average T~2~ values were higher in SCD patients compared to controls (Table [1](#ajh25727-tbl-0001){ref-type="table"}). The corresponding SvO~2~ was also higher in SCD patients (71.4 ± 4.2%) compared to healthy controls (64.1 ± 3.8%, *P* \< .001). The average T~1~ values did not differ between SCD patients and controls (Figure S1).

3.3. Baseline hemodynamic results {#ajh25727-sec-0013}
---------------------------------

Hemoglobin concentration was lower in patients compared to controls (8.8 ± 1.4 versus 13.7 ± 1.3 g/dL, *P* \< .001), which led to a lower calculated oxygen carrying capacity (CaO~2~) in patients compared to controls (515 ± 81 versus 804 ± 73 μmol O~2~/100mL blood, *P* \< .001). Oxygen delivery (DO~2~) was similar in patients compared to controls (377 ± 67 versus 367 ± 42 μmol O~2~ /100g/min, *P* = .698), due to compensatory elevated CBF in patients versus controls (74 ± 16 versus 46 ± 5 mL/100 g/min, *P* \< .001). In spite of the similar DO~2~, we observed lower OEF in patients compared to controls (27.1 ± 4.4 versus 35.3 ± 3.6%, *P* = .001). As a result, SCD patients had lower CMRO~2~ compared to controls (101.7 ± 23.6 versus 127.2 ± 19.5 μmol O~2~ /100g/min, *P* = .005) (Figure [2](#ajh25727-fig-0002){ref-type="fig"}).

![Box‐plots showing the statistical differences between adults with sickle cell disease (SCD) and controls, before (pre), and after acetazolamide (ACZ) injection. A, The T~2~ of blood was higher in patients with SCD at baseline and increased after ACZ in both groups. B, Venous oxygen saturation (SvO~2~) was higher in patients with SCD and increased after ACZ in line with increased blood volume due to vasodilation. C, Oxygen extraction fraction (OEF) was lower in patients with SCD and declined after ACZ. D, Cerebral blood flow (CBF) in the whole brain (excluding lesions) was higher in patients with SCD and increased in both groups after ACZ. The highest CBF at baseline was in a patient with comorbid moyamoya syndrome. E, Oxygen delivery was not significantly different in patients with SCD compared to controls, and increased after ACZ due to the increase in CBF. F, CMRO~2~ was lower in patients with SCD, and remained stable after ACZ in controls, but declined in patients with SCD. *P*‐values remained significant after Benjamini‐Hochberg adjustment for family‐wise error. Lines and error bars indicate mean and SD \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](AJH-95-401-g002){#ajh25727-fig-0002}

3.4. Response to acetazolamide (ACZ) challenge {#ajh25727-sec-0014}
----------------------------------------------

In order to assess if CMRO~2~ in SCD patients could be normalized by vasodilation, we repeated the measurements after acetazolamide (ACZ). We observed that there was a significant increase in venous saturation (SvO~2~) in both patients with SCD (*P* \< .001) and in healthy controls (*P* \< .001) indicating that a greater volume of oxygenated blood was delivered by the increased CBF after ACZ (Figure [2](#ajh25727-fig-0002){ref-type="fig"}). Although the absolute change in CBF was similar in patients and controls (ΔCBF was 23 and 30 mL/100 g/min), the relative change in CBF, called cerebrovascular reserve, was lower in patients with SCD versus controls (43.1 ± 12.5 versus 67.0 ± 20.0%, *P* = .003). The increase in CBF after ACZ was accompanied by a drop in OEF in patients with SCD (*P* \< .001) as well as in controls (*P* = .003) (Table [1](#ajh25727-tbl-0001){ref-type="table"}). After ACZ, CMRO~2~ declined significantly in SCD patients (−8.4 ± 16.9, *P* = .008). No significant decline was observed in healthy controls (−4.6 ± 41.3, *P* = .78), due to both the lower effect size (Cohen\'s d = 0.40 in patients and 0.13 in controls) and sample size, however it suggests that the ACZ challenge was indeed closer to isometabolic in controls than in patients.

3.5. CMRO~2~ associations with laboratory markers {#ajh25727-sec-0015}
-------------------------------------------------

In SCD patients, there was no significant difference in CMRO~2~ between patients on hydroxyurea compared to patients not taking hydroxyurea (*P* = .33) (Figure S2). We found a moderate negative correlation between CMRO~2~ and HbF% (R^2^ = 0.38, *P* \< .01), a significant but weak positive association between CMRO~2~ and reticulocyte count (R^2^ = 0.25, *P* \< .01), total bilirubin (R^2^ = 0.20, *P* \< .01) and ferritin (R^2^ = 0.14, *P* = .04). There was no association with lactate dehydrogenase (R^2^ = 0.11, *P* = .07) or HbS% (R^2^ = 0.04, *P* = .27) (Figure [3A](#ajh25727-fig-0003){ref-type="fig"}‐[F](#ajh25727-fig-0003){ref-type="fig"}). These *P*‐values remained significant after Benjamini‐Hochberg family‐wise error correction. Both OEF and CBF were also inversely associated with HbF% on univariate analysis (Figure [3G,I](#ajh25727-fig-0003){ref-type="fig"}).

![Laboratory correlates of cerebral metabolic rate of oxygen (CMRO~2~) in adults with sickle cell disease A, HbF%, B, Ferritin, C, total bilirubin, D, HbS%, E, reticulocyte count, and F, lactate dehydrogenase (LDH). Non‐hydroxyurea‐treated patients are shown in blue, hydroxyurea‐treated patients in green, and transfused patients in orange. The dotted colored lines show the fit for the non‐hydroxyurea and hydroxyurea‐treated groups, while the black solid line shows the linear fit through all patients\' data points. *P*‐values indicate significant associations. G, HbF% was inversely associated with cerebral blood flow (CBF), H, HbF% was not associated with hemoglobin concentration, I, HbF% was inversely associated with oxygen extraction fraction (OEF) \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](AJH-95-401-g003){#ajh25727-fig-0003}

3.6. Brain anatomical features and whole‐brain CMRO~2~ {#ajh25727-sec-0016}
------------------------------------------------------

We found no association between CMRO~2~ and lesion volume in patients with SCD (Spearman\'s *ρ* = −0.03, *P* = .85), and also no statistically significant correlation between OEF and lesion volume in patients with SCD (Spearman\'s *ρ* = − 0.3, *P* = .07). There was no difference in GM fraction (GM divided by total intracranial volume) between patients with SCD (mean 0.42 ± 0.05) and controls (mean 0.46 ± 0.05, *P* = 0.10). Also, there was no significant correlation between CMRO~2~ and GM fraction within the patient group (r = −0.07, *P* = 0.70) or within the control group (r = 0.47, *P* = 0.21). In patients with SCD, men had higher CMRO~2~ compared to women (*P* \< .01). There was no significant effect of age on CMRO~2~ (*P* = .20).

4. DISCUSSION {#ajh25727-sec-0017}
=============

The purpose of this study was to investigate ischemic risk in SCD patients by assessing CMRO~2~ and its response to increased flow upon vasodilation with acetazolamide. We used ASL and T~2~‐TRIR MRI with a recently introduced SCD‐specific model to non‐invasively measure CBF and cerebral SvO~2~. Our observations support our hypothesis that SCD patients have reduced OEF and CMRO~2~. This indicates that in SCD, CMRO~2~, and therefore also neuronal function, has adapted to lower oxygen availability. Our second hypothesis was that acetazolamide would normalize CMRO~2~ by increasing oxygen delivery (DO~2~), but our observations do not support this hypothesis and instead show that DO~2~ was normal in SCD patients, and that OEF and CMRO~2~ declined after acetazolamide. The higher SvO~2~ after acetazolamide suggests that arterial blood shunted directly to the venous side without oxygen extraction by the brain tissue, resulting in a reduced OEF and subsequently also reduced CMRO~2~. Our observations suggest a potentially impaired distribution of oxygen even when blood flow is artificially increased with acetazolamide, perhaps due to differences in resistance of healthy and diseased vascular beds.

4.1. Reduced oxygen utilization despite normal oxygen delivery {#ajh25727-sec-0018}
--------------------------------------------------------------

Previous studies using nitrous oxide have also shown reduced cerebral oxygen utilization in SCD and other anemias.[40](#ajh25727-bib-0040){ref-type="ref"}, [41](#ajh25727-bib-0041){ref-type="ref"} PET is the gold standard for CBF, OEF and CMRO~2~, and an early study in SCD patients found that CBF was appropriately elevated in the cortical MCA territory to conserve normal DO~2~ and average CMRO~2~ compared to controls.[5](#ajh25727-bib-0005){ref-type="ref"} In the PET study, half of the patients had CMRO~2~ values below the lowest CMRO~2~ value of controls but on average the groups did not differ. We also found no difference in DO~2~ between patients and controls due to elevated CBF as previously reported for whole‐brain and GM.[23](#ajh25727-bib-0023){ref-type="ref"}, [29](#ajh25727-bib-0029){ref-type="ref"}

4.2. Higher venous saturation {#ajh25727-sec-0019}
-----------------------------

We found higher T~2~ in patients with SCD in our study, which denotes increased venous oxygen saturation (SvO~2~),[42](#ajh25727-bib-0042){ref-type="ref"} and is in agreement with recent reports of increased SvO~2~ in children and adults with SCD using T~2~‐TRUST as well as susceptibility MRI,[21](#ajh25727-bib-0021){ref-type="ref"}, [22](#ajh25727-bib-0022){ref-type="ref"}, [43](#ajh25727-bib-0043){ref-type="ref"} but in contrast to other reports[44](#ajh25727-bib-0044){ref-type="ref"} which differ due to differences in the choice of calibration model. Nevertheless, elevated SvO~2~ in SCD may indicate impaired oxygen extraction as has been reported in the peripheral tissue[45](#ajh25727-bib-0045){ref-type="ref"} and may explain the high risk of tissue hypoxia as well as infarction in SCD.

4.3. Reduced oxygen extraction fraction {#ajh25727-sec-0020}
---------------------------------------

We observed reduced OEF in adults with SCD with an MR technique that measures post‐capillary venous OEF,[33](#ajh25727-bib-0033){ref-type="ref"} which is spatially and temporally different from the ASE technique which measures OEF locally in deep WM tissue and has found elevated OEF in children with SCD.[27](#ajh25727-bib-0027){ref-type="ref"}, [28](#ajh25727-bib-0028){ref-type="ref"}, [46](#ajh25727-bib-0046){ref-type="ref"} Fields, Guilliams, Ford and colleagues consistently find increased OEF in the deep WM tissue, which, in steno‐occlusive disease, reflects stage 2 hemodynamic compromise when OEF starts to compensate for critically low CBF to try to maintain DO~2.~ [47](#ajh25727-bib-0047){ref-type="ref"} In children with SCD, this increased OEF in WM may indicate that compensatory mechanisms are activated to maintain CMRO~2~. Reduced OEF in whole brain in adults with SCD may indicate that hemodynamic compromise has not reached a critical level, or that our globally measured SvO~2~, OEF, and CMRO~2~ were dominated by the metabolic activity of the GM, which may be stealing from the WM. Indeed, CBF might preferentially be distributed to maintain DO~2~ in the GM, where many neuronal processes must be fed, by using the cerebrovascular reserve that is still available, and hence keeping OEF normal, as others have found using global venous technqiues.[22](#ajh25727-bib-0022){ref-type="ref"}, [23](#ajh25727-bib-0023){ref-type="ref"}

4.4. Homeostatic relationship between CBF and OEF after acetazolamide {#ajh25727-sec-0021}
---------------------------------------------------------------------

If the low CMRO~2~ were just the result of flow limitation, acetazolamide would be expected to ameliorate the reduced metabolism in SCD patients by dilating the vessels and increasing delivery of oxygenated blood. As anticipated, CBF increased and OEF declined in both groups in response to acetazolamide.[48](#ajh25727-bib-0048){ref-type="ref"} There was no change detected in CMRO~2~ in healthy controls which is supported by a previous study using susceptometry‐based oximetry with hypercapnia challenge.[49](#ajh25727-bib-0049){ref-type="ref"} Interestingly, we observed a small reduction in CMRO~2~ in patients with SCD, indicating a mismatch between CBF and OEF. A power analysis showed that there was 95% power to detect a reduction in the SCD group, while there was 10% power in the control group due to the lower sample size. Normalizing CBF and increasing oxygen carrying capacity with transfusions could shed light on a potential mechanism explaining this mismatch. However, studies on children with SCD addressing acute effects of transfusions on global or regional OEF and CMRO~2~ have not found significant changes in CMRO~2~, possibly due to sufficiently elevated compensatory CBF before transfusion.[46](#ajh25727-bib-0046){ref-type="ref"}, [50](#ajh25727-bib-0050){ref-type="ref"} An alternative explanation for the drop in CMRO~2~ is that carbonic anhydrase inhibition with acetazolamide may influence the Hb‐O~2~ dissociation curve due to the increased acidotic environment, leading to tighter Hb‐O~2~ binding and lower OEF and CMRO~2~.

4.5. Heterogeneous oxygen distribution after acetazolamide {#ajh25727-sec-0022}
----------------------------------------------------------

The ability of vessels to dilate will govern their vascular resistance which will determine the favorable dispersal of blood towards healthier vascular beds. This would suggest that there exists heterogeneity in the blood flow distributed to different vascular beds, and could explain the preferential localization of ischemic lesions in specific low‐flow areas.[27](#ajh25727-bib-0027){ref-type="ref"} It is known that blood arrival times are heterogeneous due to the anatomic architecture of the cerebral vessels,[51](#ajh25727-bib-0051){ref-type="ref"} but downstream capillary transit times may also reflect certain regional differences. For instance, recent work has shown that heterogenous blood distribution can lead to reduced OEF and CMRO~2~ in the presence or introduction of increased transit time heterogeneity,[30](#ajh25727-bib-0030){ref-type="ref"}, [52](#ajh25727-bib-0052){ref-type="ref"} which could be an explanation for why we found lower OEF and CMRO~2~ after acetazolamide. Acetazolamide would induce dilation only in healthy vessels which are able to dilate, leading to lower resistance and more blood flow. For diseased vessels, acetazolamide would have little effect, leading to no or little change in blood flow and hence no change in oxygen delivery. The surplus oxygen is delivered to healthy vascular beds due to lower resistance, but have neither the additional oxygen requirement nor a sufficient oxygen diffusion gradient for oxygen to unload, so oxygen flows to the venous side (we found increased SvO~2~). Hence, reduced CMRO~2~ might only occur if there exists a heterogeneity in the ability of different vascular beds to dilate. We cannot exclude the possibility that chronically anemic patients may also lose capillary surface area through vascular remodeling; but the imaging used in this study cannot quantify vascular surface area.

4.6. CMRO~2~ and ischemic risk {#ajh25727-sec-0023}
------------------------------

In this study there was no association between CMRO~2~ and lesion volume contrary to what has been reported in patients with multiple sclerosis.[53](#ajh25727-bib-0053){ref-type="ref"} We observed a higher prevalence of lesions in the WM where CBF is low, and recent studies show that although OEF may be elevated in children in these locations,[27](#ajh25727-bib-0027){ref-type="ref"}, [28](#ajh25727-bib-0028){ref-type="ref"} CMRO~2~ is primarily high in more physiologically active GM.[54](#ajh25727-bib-0054){ref-type="ref"} Global CMRO~2~ measurements may not reflect local changes in metabolism, so regional measurements may better identify areas of particular risk for SCIs. Hence, the lack of association between global CMRO~2~ and lesion volumes in WM can be explained by the high CBF in GM, masking the reduced CMRO~2~ in areas with lesions. The role of oxygenation in the development and progression of lesions is particularly challenging to study, because lesions are not detected at the time they occur, and can therefore represent periods of acute anemia experienced a long time before lesion detection with MRI. So, the lack of association between CMRO~2~ and lesions in our study does not necessarily mean that there is no relationship, but rather that our cross‐sectional design was poorly suited to detect it, and longitudinal studies following young patients into adulthood would be insightful in this respect.

4.7. CMRO~2~ and HbF {#ajh25727-sec-0024}
--------------------

We found that CMRO~2~ was inversely associated with HbF, which was not found by Herold *et al*.[5](#ajh25727-bib-0005){ref-type="ref"} In univariate analyses, Fields et al. recently found that SCD patients with higher HbF levels also had lower OEF in a comparison between patients treated with hydroxyurea and not treated with hydroxyurea.[55](#ajh25727-bib-0055){ref-type="ref"} This is not surprising if OEF elevations are related to disease severity as they suggest, but would be surprising if OEF elevations are related to improved oxygen extraction. If higher HbF is associated with low oxygen extraction fraction, then this could suggest that HbF has a tighter Hb‐O~2~ binding affinity, leading to less efficient oxygen unloading. Finally, the inverse relationship between CBF and HbF is supported by literature in sickle cell mice,[56](#ajh25727-bib-0056){ref-type="ref"} which Cui *et al* [56](#ajh25727-bib-0056){ref-type="ref"} suggest may be related to lower sickling, reduced oxidative stress, improved NO activity or improved oxygen carrying capacity and delivery. Thus, the balance between oxygen delivery and extraction may be perturbed in the presence of HbF whereby more oxygen is delivered than can be extracted. Furthermore, as discussed above, variations in capillary transit time and shunting may mean that there is less time and insufficient oxygen diffusion gradient to unload oxygen resulting in a lower global OEF and subsequently lower global CMRO~2~. Together, our findings suggest that reduced CMRO~2~ could partly be mediated by the effect of higher HbF levels on both OEF and CBF. However, the HbF correlation with CMRO~2~ was from univariate analysis, and future studies with larger cohorts will likely show that the effects of HbF on CMRO~2~ are mitigated by covariation with HbA, so the driving factor in predicting CMRO~2~ requires further investigation.

4.8. Limitations {#ajh25727-sec-0025}
----------------

A general limitation of MRI‐derived CMRO~2~ is error propagation of the individual measurements of CBF, OEF and CaO~2~ due to multiplication.[57](#ajh25727-bib-0057){ref-type="ref"} While there is currently no direct MRI‐CMRO~2~ measurement, we attempted to reduce errors in CBF by correcting for differences in T1 of blood, arterial transit time and labeling efficiency.[26](#ajh25727-bib-0026){ref-type="ref"} Another limitation of CMRO~2~ calculation from T~2~‐TRIR MRI is the reliance on a model to obtain OEF values. A recent study has highlighted the importance of model choice in calculating SvO~2~ (and subsequent OEF), which can explain the observed differences of elevated,[21](#ajh25727-bib-0021){ref-type="ref"}, [28](#ajh25727-bib-0028){ref-type="ref"}, [44](#ajh25727-bib-0044){ref-type="ref"}, [46](#ajh25727-bib-0046){ref-type="ref"}, [50](#ajh25727-bib-0050){ref-type="ref"} reduced,[22](#ajh25727-bib-0022){ref-type="ref"} or unchanged[21](#ajh25727-bib-0021){ref-type="ref"}, [23](#ajh25727-bib-0023){ref-type="ref"} CMRO~2~ in patients with SCD. Until recently, two models were available for T~2~‐derived SvO~2~; the first was calibrated in bovine blood in a wide range of Hct (35‐55%) considered to be a healthy range,[58](#ajh25727-bib-0058){ref-type="ref"}, [59](#ajh25727-bib-0059){ref-type="ref"} and the second was calibrated in human sickle cell blood in a slightly smaller but more appropriate range of Hct for anemia of 24‐40%.[22](#ajh25727-bib-0022){ref-type="ref"} The bovine model shows higher OEF in SCD (lower SvO~2~) compared to controls,[21](#ajh25727-bib-0021){ref-type="ref"}, [44](#ajh25727-bib-0044){ref-type="ref"} but it should be noted that the model is biased at low Hct. On the other hand, the sickle cell model previously showed lower OEF in SCD (higher SvO~2~) compared to controls,[22](#ajh25727-bib-0022){ref-type="ref"} a finding that is supported here and also by an independent susceptibility MRI study showing higher SvO~2~ in SCD compared to controls.[43](#ajh25727-bib-0043){ref-type="ref"} The main difference between the sickle‐cell model and healthy human blood model is that the sickle‐cell model does not show dependence on Hct which is most probably due to the narrow range of Hct used for calibration or that Hct is too low to influence the measured T~2~ value. A recent approach has used subject‐specific calibration resulting in OEF similar to the sickle‐cell model.[23](#ajh25727-bib-0023){ref-type="ref"} Although validation of the models in SCD is still warranted by comparison with PET, which is the current gold standard for OEF and CMRO~2~ measurements, our choice for the sickle cell model is justified by the fact that it was calibrated over a relevant hematocrit range for our population. We assumed arterial oxygen saturation to be 0.98 which may have been inaccurate in SCD patients, but given the median saturation of 0.97 measured clinically in two studies including more than 100 children and 89 adults with SCD in steady‐state respectively[60](#ajh25727-bib-0060){ref-type="ref"}, [61](#ajh25727-bib-0061){ref-type="ref"} we expect that any resulting error in SaO~2~ and CaO~2~ will be small, particularly because we did not include patients with proven pulmonary hypertension or severe cardiomyopathy, both of which may result in low arterial saturation.

5. CONCLUSION {#ajh25727-sec-0026}
=============

In this study, we used T~2~‐TRIR and ASL MRI to measure reduced CMRO~2~ in adults with SCD. Overall, oxygen delivery to the brain was normal in SCD patients. However, specific capillary beds may have adapted to chronic low oxygen delivery due to anemia as differences in dilatory capacity and resistance may arise depending on metabolic requirements. We conclude firstly that CMRO~2~ does not improve in response to transient changes in oxygen availability induced by acetazolamide in SCD patients, despite the increase in CBF, and secondly, that this worsening CMRO~2~ in SCD patients may be due to increased capillary transit time heterogeneity exacerbated by high flow.[30](#ajh25727-bib-0030){ref-type="ref"}, [52](#ajh25727-bib-0052){ref-type="ref"}
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Supplementary figure S1. Boxplot including individual data points of T~1~ blood values measured in the venous sagittal sinus with T~2~‐TRIR. T~1~ blood was not significantly different (T‐test: P=0.23) between healthy controls and patients with SCD.

Supplementary figure S2. Boxplot including individual data points of CMRO~2~ in patients with SCD not treated with hydroxyurea (left) and those treated with hydroxyurea (right). CMRO~2~ was not significantly different between the groups.
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